A historic shift in Canadian drug policy has happened, as the regulators announce the availability of psilocybin fungi for therapeutic purposes. Previously, these substances were severely restricted, but a mounting body of evidence suggests they could offer benefits for emotional issues like depression. The new policy represents a key step toward r